Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CASP2 | P42575 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | NAAA | Q02083 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26700970 | 0.99 | HPGD (0.40) | GLP1RHPGDCASP2TSHRMEN1 | |
| SCHEMBL29299850 | 0.99 | HPGD (0.40) | GLP1RHPGDCASP2TSHRMEN1 | |
| SCHEMBL23319057 | 0.99 | HPGD (0.40) | GLP1RHPGDCASP2TSHRMEN1 | |
| SCHEMBL29299838 | 0.97 | HPGD (0.41) | GLP1RHPGDCASP2TSHRMEN1 | |
| SCHEMBL29299575 | 0.94 | HPGD (0.41) | GLP1RHPGDCASP2TSHRMEN1 | |
| SCHEMBL26866029 | 0.93 | GLP1R (0.42) | GLP1RHPGDCASP2TSHRMEN1 | |
| SCHEMBL25792664 | 0.93 | HPGD (0.42) | GLP1RHPGDCASP2TSHRMEN1 | |
| SCHEMBL25480495 | 0.90 | CNR1 (0.44) | GLP1RHPGDCASP2TSHRMEN1 | |
| SCHEMBL29302105 | 0.87 | CASP2 (0.54) | GLP1RCASP2NAAA | |
| SCHEMBL26034458 | 0.87 | TSHR (0.41) | HPGDTSHRMEN1KMT2ACNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11634450-B2 | DOT1L degraders and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-04-25 | — | — | US | disclosed |
| US-20210130386-A1 | DOT1L DEGRADERS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130386-A1 | DOT1L DEGRADERS AND USES THEREOF | CRBN, CUL1, STUB1 | GLP1R 3081/4885HPGD 4011/4885CASP2 2674/4885 |
| US-11634450-B2 | DOT1L degraders and uses thereof | CRBN, CUL1, STUB1 | GLP1R 3081/4885HPGD 4011/4885CASP2 2674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.